Showing papers by "Yu Shyr published in 1997"
TL;DR: It is shown that the antioxidants pyrrolidinedithiocarbamate and vitamin E induce apoptosis in CRC Cells, and chemotherapeutic agents administered in the presence of antioxidants may provide a novel therapy for colorectal cancer.
Abstract: Colorectal cancer (CRC) is the second leading cause of cancer deaths in the United States. Five-fluorouracil (5FU) remains the single most effective treatment for advanced disease, despite a response rate of only 20%. Herein, we show that the antioxidants pyrrolidinedithiocarbamate and vitamin E induce apoptosis in CRC cells. This effect is mediated by induction of p21WAF1/CIP1, a powerful inhibitor of the cell cycle, through a mechanism involving C/EBPbeta (a member of the CCAAT/enhancer binding protein family of transcription factors), independent of p53. Antioxidants significantly enhance CRC tumor growth inhibition by cytotoxic chemotherapy in vitro (5FU and doxorubicin) and in vivo (5FU). Thus, chemotherapeutic agents administered in the presence of antioxidants may provide a novel therapy for colorectal cancer.
353 citations
TL;DR: Access blood flow measured by either Dilution or Doppler is a reliable indicator of subsequent short-term thrombosis risk and will likely become the method of choice for screening of PTFE vascular access dysfunction in hemodialysis patients.
252 citations
TL;DR: The data show the absence of a diurnal variation of BP in Dialysis patients and lower BP in hemodialysis patients compared with peritoneal dialysis patients, and prehemodialysis and postdialysis BP can be used to model mean BP levels.
79 citations
Journal Article•
TL;DR: In this paper, a prospective phase II study was conducted to determine the response rate, toxicity profile, and survival rate among patients with locally advanced unresectable non-small cell lung cancer receiving concurrent weekly paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ), carboplatin, and hyperfractionated radiation therapy.
27 citations
Journal Article•
TL;DR: Preliminary results indicate that paclitaxel/5-fluorouracillleucovorin is an active, well-tolerated regimen for treating metastatic breast cancer.
14 citations
TL;DR: Investigating the effects of alcohol on the fibrinolytic components in a more simplified tissue culture system found divergent responses at the transcriptional level are associated with an increase in the extracellular t-PA activity in the conditioned medium of cells exposed to ethanol.
13 citations
TL;DR: Intravenous albunex was more effective than agitated saline in enhancing incomplete Doppler echocardiography spectra for tricuspid regurgitation without a significant alteration in the maximal detected velocity.
Abstract: Intravenous albunex was more effective than agitated saline in enhancing incomplete Doppler echocardiography spectra for tricuspid regurgitation without a significant alteration in the maximal detected velocity. The optimal dose was 1 to 4 ml in most patients, using an initial dose of 1 ml and titrating further dosing on the basis of the initial contrast effect.
11 citations
TL;DR: Combining daily protracted cisplatin and etoposide with concurrent thoracic irradiation with concurrent chest irradiation in patients with locally advanced unresectable NSCLC yields a high overall response rate and a median survival that is at least comparable to other combined modality trials.
Abstract: Purpose: A Phase II study to evaluate the response rate and toxicity of daily protracted cisplatin and etoposide with concurrent chest irradiation in patients with locally advanced, unresectable nonsmall cell lung cancer (NSCLC). Methods and Materials: Twenty-one patients with histologically confirmed locally advanced inoperable NSCLC (Stage IIIA and IIIB) were entered on study. Radiotherapy consisted of 50.4 Gy in 1.8 Gy fractions followed by a 10 Gy boost in 2 Gy fractions. Chemotherapy included the following: Cisplatin was given at 5 mg/m 2 i.v. Monday-Friday before RT weeks 1–6. Etoposide was given at 25 mg/m 2 i.v. M-F weeks 1, 2, 5, and 6, with 50 mg/m 2 p.o. daily on the same weekends. Because of severe myelosuppression in the first two patients, etoposide only was subsequently changed to 20 mg/m 2 i.v. M-F weeks 1, 2, 5, and 6. Results: Twenty patients were eligible and evaluable. The overall response rate was 65% (95% confidence interval 41–85%). The median progression-free survival was 43 weeks. The median overall survivval was 50.2 weeks with a 1-year survival rate of 45%. Five patients (25%) developed severe radiation pneumonitis, leading to early closure of the study. Conclusions: Combining daily protracted cisplatin and etoposide with concurrent thoracic irradiation in patients with locally advanced unresectable NSCLC yield a high overall response rate and a median survival that is at least comparable to other combined modality trials. However, future studies using protracted radiosensitizing chemotherapy should be approached cautiously in light of the high incidence of severe radiation pneumonitis encountered in this trial.
10 citations
TL;DR: In this paper, the authors used Yate's missing plot technique to derive the formula for substitution in a missing plot in a general incomplete block design, where blocks are assumed to be independent normal.
Abstract: In this paper, Yate's missing plot technique is used to derive the formula for substitution in a missing plot in a general incomplete block design, where blocks are assumed to be independent normal. The use of penalized normal equations, using BLUPS, makes this task simpler.